<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Ovaleap, INN-follitropin alfa</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#243F60;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#243F60;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:#404040;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-link:"Title Char";
	margin:0in;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-link:"Title Char";
	margin:0in;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-link:"Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	letter-spacing:.75pt;
	font-style:italic;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin:0in;
	text-indent:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.8in;
	margin-bottom:0in;
	margin-left:.8in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#4F81BD;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.5pt;
	font-family:Consolas;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Cambria",serif;
	color:#243F60;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Cambria",serif;
	color:#243F60;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Cambria",serif;
	color:#404040;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;
	font-family:"Times New Roman",serif;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Times New Roman",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";
	font-family:"Times New Roman",serif;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;
	font-family:"Times New Roman",serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:Consolas;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:Consolas;}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:Consolas;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Times New Roman",serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:normal;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;
	font-family:"Times New Roman",serif;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;
	color:#4F81BD;
	letter-spacing:.75pt;
	font-style:italic;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
300&nbsp;IU/0.5&nbsp;mL solution for injection</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
450&nbsp;IU/0.75&nbsp;mL solution for injection</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
900&nbsp;IU/1.5&nbsp;mL solution for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>2.       QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each mL of the solution
contains 600&nbsp;IU (equivalent to 44&nbsp;micrograms) follitropin alfa*.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB style='color:black'>Ovaleap
300&nbsp;IU/0.5&nbsp;mL solution for injection</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each cartridge contains
300&nbsp;IU (equivalent to 22&nbsp;micrograms) follitropin alfa in 0.5&nbsp;mL
solution for injection.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB style='color:black'>Ovaleap
450&nbsp;IU/0.75&nbsp;mL solution for injection</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each cartridge contains
450&nbsp;IU (equivalent to 33&nbsp;micrograms) follitropin alfa in 0.75&nbsp;mL
solution for injection.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB style='color:black'>Ovaleap 900&nbsp;IU/1.5&nbsp;mL
solution for injection</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each cartridge contains
900&nbsp;IU (equivalent to 66&nbsp;micrograms) follitropin alfa in 1.5&nbsp;mL
solution for injection.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>*Follitropin alfa</span><span
lang=EN-GB style='color:black'> (recombinant human follicle&#8209;stimulating
hormone [r&#8209;hFSH]) is produced in Chinese Hamster Ovary Cells
(CHO&nbsp;DHFR<sup>-</sup>) by recombinant DNA technology.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>Excipient(s)
with known effect:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Ovaleap contains 0.02 mg per mL of benzalkonium chloride</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Ovaleap </span><span lang=EN-GB style='color:black'>contains
</span><span lang=EN-GB style='color:black'>10.0 mg per mL of benzyl alcohol</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>For the full list of
excipients, see section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Solution for
injection (injection).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Clear, colourless
solution.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The pH of the solution
is 6.8-7.2.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>4.       </span></b><b><span
lang=EN-GB>CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>In adult women</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='color:black'>        Anovulation (including
polycystic ovarian syndrome) in women who have been unresponsive to treatment
with clomifene citrate.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        Stimulation of multifollicular
development in women undergoing superovulation for assisted reproductive
technologies (ART) such as <i>in vitro </i>fertilisation (IVF), gamete
intra-fallopian transfer and zygote intra&#8209;fallopian transfer.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        Ovaleap in association with a
luteinising hormone (LH) preparation is recommended for the stimulation of
follicular development in women with severe LH and FSH deficiency. In clinical
trials these patients were defined by an endogenous serum LH level
&lt;&nbsp;1.2&nbsp;IU/L.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>In adult men</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='color:black'>        Ovaleap is indicated for
the stimulation of spermatogenesis in men who have congenital or acquired
hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin
(hCG) therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.2     Posology
and method of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Treatment with follitropin alfa should be initiated under
the supervision of a physician experienced in the treatment of fertility
disorders.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The dose
recommendations given for follitropin alfa are those in use for urinary FSH.
Clinical assessment of follitropin alfa indicates that its daily doses,
regimens of administration and treatment monitoring procedures should not be
different from those currently used for urinary FSH&#8209;containing medicinal
products. It is advised to adhere to the recommended starting doses indicated
below.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Comparative clinical
studies have shown that on average patients require a lower cumulative dose and
shorter treatment duration with follitropin alfa compared with urinary FSH.
Therefore, it is considered appropriate to give a lower total dose of
follitropin alfa than generally used for urinary FSH, not only in order to
optimise follicular development but also to minimise the risk of unwanted
ovarian hyperstimulation (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Women with
anovulation (including polycystic ovarian syndrome)</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Follitropin alfa may be
given as a course of daily injections. In menstruating women treatment should
commence within the first 7&nbsp;days of the menstrual cycle.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>A commonly used regimen
commences at 75&#8209;150&nbsp;IU FSH daily and is increased preferably by 37.5
or 75&nbsp;IU at 7 or preferably 14&nbsp;day intervals if necessary, to obtain
an adequate, but not excessive, response. Treatment should be tailored to the
individual patients response as assessed by measuring follicle size by
ultrasound and/or oestrogen secretion. The maximal daily dose is usually not
higher than 225&nbsp;IU FSH. If a patient fails to respond adequately after
4&nbsp;weeks of treatment, that cycle should be abandoned and the patient
should undergo further evaluation after which she may recommence treatment at a
higher starting dose than in the abandoned cycle.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>When an optimal
response is obtained, a single injection of 250&nbsp;micrograms recombinant
human choriogonadotropin alfa (r-hCG) or 5,000&nbsp;IU up to 10,000&nbsp;IU hCG
should be administered 24&#8209;48&nbsp;hours after the last follitropin alfa
injection. The patient is recommended to have coitus on the day of, and the day
following, hCG administration. Alternatively intrauterine insemination (IUI)
may be performed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If an excessive
response is obtained, treatment should be stopped and hCG withheld (see section
4.4). Treatment should recommence in the next cycle at a dose lower than that
of the previous cycle.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB
style='color:black'>Women undergoing ovarian stimulation for multiple
follicular development prior to in vitro fertilisation or other ART</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>A commonly used regimen for superovulation involves the
administration of 150&#8209;225&nbsp;IU of follitropin alfa daily, commencing
on days 2 or 3 of the cycle. Treatment is continued until adequate follicular
development has been achieved (as assessed by monitoring of serum oestrogen
concentrations and/or ultrasound examination), with the dose adjusted according
to the patients response, to usually not higher than 450&nbsp;IU daily. In
general adequate follicular development is achieved on average by the tenth day
of treatment (range 5 to 20&nbsp;days).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>A single injection of
250&nbsp;micrograms r&#8209;hCG or 5,000&nbsp;IU up to 10,000&nbsp;IU hCG is
administered 24&#8209;48&nbsp;hours after the last follitropin alfa injection
to induce final follicular maturation.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Down&#8209;regulation
with a gonadotropin&#8209;releasing hormone (GnRH) agonist or antagonist is now
commonly used in order to suppress the endogenous LH surge and to control tonic
levels of LH. In a commonly used protocol, follitropin alfa is started
approximately 2&nbsp;weeks after the start of agonist treatment, both being
continued until adequate follicular development is achieved. For example,
following two&nbsp;weeks of treatment with an agonist, 150&#8209;225&nbsp;IU
follitropin alfa are administered for the first 7&nbsp;days. The dose is then
adjusted according to the ovarian response.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Overall experience with
IVF indicates that in general the treatment success rate remains stable during
the first four attempts and gradually declines thereafter.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Women with
anovulation resulting from severe LH and FSH deficiency</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In LH and FSH deficient
women (hypogonadotropic hypogonadism), the objective of follitropin alfa
therapy in association with lutropin alfa is to develop a single mature
Graafian follicle from which the oocyte will be liberated after the
administration of hCG. Follitropin alfa should be given as a course of daily
injections simultaneously with lutropin alfa. Since these patients are
amenorrhoeic and have low endogenous oestrogen secretion, treatment can
commence at any time.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>A recommended regimen
commences at 75&nbsp;IU of lutropin alfa daily with 75&#8209;150&nbsp;IU FSH.
Treatment should be tailored to the individual patients response as assessed
by measuring follicle size by ultrasound and oestrogen response.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If an FSH dose increase
is deemed appropriate, dose adaptation should preferably be after 7&#8209;14&nbsp;day
intervals and preferably by 37.5&#8209;75&nbsp;IU increments. It may be
acceptable to extend the duration of stimulation in any one cycle to up to
5&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>When an optimal
response is obtained, a single injection of 250&nbsp;micrograms r&#8209;hCG or
5,000&nbsp;IU up to 10,000&nbsp;IU hCG should be administered 24&#8209;48&nbsp;hours
after the last follitropin alfa and lutropin alfa injections. The patient is
recommended to have coitus on the day of, and on the day following, hCG
administration. Alternatively, IUI may be performed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Luteal phase support
may be considered since lack of substances with luteotropic activity (LH/hCG)
after ovulation may lead to premature failure of the corpus luteum.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If an excessive
response is obtained, treatment should be stopped and hCG withheld. Treatment
should recommence in the next cycle at a dose of FSH lower than that of the
previous cycle.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Men with
hypogonadotropic hypogonadism</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Follitropin alfa should
be given at a dose of 150&nbsp;IU three times a week, concomitantly with hCG,
for a minimum of 4&nbsp;months. If after this period, the patient has not
responded, the combination treatment may be continued; current clinical
experience indicates that treatment for at least 18&nbsp;months may be
necessary to achieve spermatogenesis.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB
style='color:black'>Special population</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Elderly population</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>There is no relevant
use of follitropin alfa in the elderly population. Safety and effectiveness of
follitropin alfa in elderly patients have not been established.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Renal or hepatic
impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Safety, efficacy and
pharmacokinetics of follitropin alfa in patients with renal or hepatic
impairment have not been established.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Paediatric population</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>There is no relevant use of follitropin alfa in the
paediatric population.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Method of
administration</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Ovaleap is intended for
subcutaneous use. The first injection should be performed under direct medical
supervision. Self-administration should only be performed by patients who are
well motivated, adequately trained and have access to expert advice.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>As the multidose
cartridge is intended for several injections, clear instructions should be
provided to the patients to avoid misuse of the medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The Ovaleap cartridge
is designed for use in conjunction with the Ovaleap Pen only, which is
separately available. For instructions on the administration with the<a
name="OLE_LINK3"> Ovaleap Pen</a>, see section 6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        Hypersensitivity to the active
substance follitropin alfa, FSH or to any of the excipients</span><span
lang=EN-GB> </span><span lang=EN-GB style='color:black'>listed in section 6.1;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        tumours of the hypothalamus or
pituitary gland;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        ovarian enlargement or ovarian cyst not
due to polycystic ovarian syndrome;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        gynaecological haemorrhages of unknown
aetiology;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        ovarian, uterine or mammary carcinoma.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>Ovaleap must not be used when an effective
response cannot be obtained, such as:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        primary ovarian failure;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        malformations of sexual organs
incompatible with pregnancy;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        fibroid tumours of the uterus incompatible
with pregnancy;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='color:black'>        primary testicular insufficiency.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><i><u><span lang=EN-GB>Traceability</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>In order to improve the traceability of
biological medicinal products, the trade name and batch number of the
administered medicinal product should be clearly recorded in the patient file.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>General</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Follitropin alfa is a
potent gonadotropic substance capable of causing mild to severe adverse
reactions and should only be used by physicians who are thoroughly familiar
with infertility problems and their management.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Gonadotropin therapy
requires a certain time commitment by physicians and supportive health
professionals, as well as the availability of appropriate monitoring
facilities. In women, safe and effective use of follitropin alfa calls for
monitoring of ovarian response with ultrasound, alone or preferably in
combination with measurement of serum oestradiol levels, on a regular basis.
There may be a degree of interpatient variability in response to FSH
administration, with a poor response to FSH in some patients and exaggerated
response in others. The lowest effective dose in relation to the treatment
objective should be used in both men and women.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB
style='color:black'>Porphyria</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Patients with porphyria or a family history of porphyria
should be closely monitored during treatment with follitropin alfa.
Deterioration or a first appearance of this condition may require cessation of
treatment.</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Treatment in
women</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Before starting
treatment, the couples infertility should be assessed as appropriate and
putative contraindications for pregnancy evaluated. In particular, patients
should be evaluated for hypothyroidism, adrenocortical deficiency,
hyperprolactinemia and appropriate specific treatment given.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Patients undergoing
stimulation of follicular growth, whether as treatment for anovulatory
infertility or ART procedures, may experience ovarian enlargement or develop
hyperstimulation. Adherence to recommended follitropin alfa dose and regimen of
administration and careful monitoring of therapy will minimise the incidence of
such events. For accurate interpretation of the indices of follicle development
and maturation, the physician should be experienced in the interpretation of
the relevant tests.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In clinical trials, an
increase of the ovarian sensitivity to follitropin alfa was shown when
administered with lutropin alfa. If an FSH dose increase is deemed appropriate,
dose adaptation should preferably be at 7&#8209;14&nbsp;day intervals and
preferably with 37.5&#8209;75&nbsp;IU increments.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>No direct comparison of
follitropin alfa/LH versus human menopausal gonadotropin (hMG) has been
performed. Comparison with historical data suggests that the ovulation rate
obtained with follitropin alfa/LH is similar to that obtained with hMG.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Ovarian
Hyperstimulation Syndrome (OHSS)</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>A certain degree of
ovarian enlargement is an expected effect of controlled ovarian stimulation. It
is more commonly seen in women with polycystic ovarian syndrome and usually
regresses without treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In distinction to
uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself
with  increasing degrees of severity. It comprises marked ovarian enlargement,
high serum sex steroids and an increase in vascular permeability which can
result in an accumulation of fluid in the peritoneal, pleural and, rarely, in
the pericardial cavities.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The following
symptomatology may be observed in severe cases of OHSS: abdominal pain,
abdominal distension, severe ovarian enlargement, weight gain, dyspnoea,
oliguria and gastrointestinal symptoms including nausea, vomiting and
diarrhoea. Clinical evaluation may reveal hypovolaemia, haemoconcentration,
electrolyte imbalances, ascites, haemoperitoneum, pleural effusions,
hydrothorax, or acute pulmonary distress. Very rarely, severe OHSS may be
complicated by ovarian torsion or thromboembolic events such as pulmonary
embolism, ischaemic stroke or myocardial infarction.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Independent risk
factors for developing OHSS include polycystic ovarian syndrome high absolute
or rapidly rising serum oestradiol levels (e.g. &gt;&nbsp;900&nbsp;pg/mL or
&gt;&nbsp;3,300&nbsp;pmol/L in anovulation; &gt;&nbsp;3,000&nbsp;pg/mL or
&gt;&nbsp;11,000&nbsp;pmol/L in ART) and large number of developing ovarian
follicles (e.g. &gt;&nbsp;3&nbsp;follicles of &#8805;&nbsp;14&nbsp;mm in
diameter in anovulation; &#8805;&nbsp;20&nbsp;follicles of
&#8805;&nbsp;12&nbsp;mm in diameter in ART).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Adherence to
recommended follitropin alfa dose and regimen of administration can minimise the
risk of ovarian hyperstimulation (see sections 4.2 and 4.8). Monitoring of
stimulation cycles by ultrasound scans as well as oestradiol measurements are
recommended to early identify risk factors.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>There is evidence to
suggest that hCG plays a key role in triggering OHSS and that the syndrome may
be more severe and more protracted if pregnancy occurs. Therefore, if signs of
ovarian hyperstimulation occur such as serum oestradiol level
&gt;&nbsp;5,500&nbsp;pg/mL or &gt;&nbsp;20,200&nbsp;pmol/L and/or
&#8805;&nbsp;40&nbsp;follicles in total, it is recommended that hCG be withheld
and the patient be advised to refrain from coitus or to use barrier
contraceptive methods for at least 4&nbsp;days. OHSS may progress rapidly
(within 24&nbsp;hours) or over several days to become a serious medical event.
It most often occurs after hormonal treatment has been discontinued and reaches
its maximum at about 7 to 10&nbsp;days following treatment. Therefore, patients
should be followed for at least 2&nbsp;weeks after hCG administration.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In ART, aspiration of
all follicles prior to ovulation may reduce the occurrence of hyperstimulation.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Mild or moderate OHSS
usually resolves spontaneously. If severe OHSS occurs, it is recommended that
gonadotropin treatment be stopped if still ongoing and that the patient be
hospitalised and appropriate therapy be started.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>Multiple pregnancy</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>In patients undergoing ovulation induction, the incidence
of multiple pregnancy is increased compared with natural conception. The
majority of multiple conceptions are twins. Multiple pregnancy, especially of
high order, carries an increased risk of adverse maternal and perinatal
outcomes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>To minimise the risk of
multiple pregnancy, careful monitoring of ovarian response is recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In patients undergoing
ART procedures the risk of multiple pregnancy is related mainly to the number
of embryos replaced, their quality and the patient age.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The patients should be
advised of the potential risk of multiple births before starting treatment.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Pregnancy loss</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The incidence of
pregnancy loss by miscarriage or abortion is higher in patients undergoing
stimulation of follicular growth for ovulation induction or ART than following
natural conception.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Ectopic pregnancy</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Women with a history of
tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained
by spontaneous conception or with fertility treatments. The prevalence of
ectopic pregnancy after ART, was reported to be higher than in the general
population.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Reproductive system
neoplasms</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>There have been reports
of ovarian and other reproductive system neoplasms, both benign and malignant,
in women who have undergone multiple treatment regimens for infertility
treatment. It is not yet established whether or not treatment with
gonadotropins increases the risk of these tumours in infertile women.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Congenital
malformation</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The prevalence of
congenital malformations after ART may be slightly higher than after
spontaneous conceptions. This is thought to be due to differences in parental
characteristics (e.g. maternal age, sperm characteristics) and multiple
pregnancies.</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Thromboembolic
events</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In women with recent or
ongoing thromboembolic disease or women with generally recognised risk factors
for thromboembolic events, such as personal or family history, treatment with
gonadotropins may further increase the risk for aggravation or occurrence of
such events. In these women, the benefits of gonadotropin administration need
to be weighed against the risks. It should be noted however that pregnancy
itself as well as OHSS also carry an increased risk of thromboembolic events.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Treatment in men</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Elevated endogenous FSH
levels are indicative of primary testicular failure. Such patients are
unresponsive to follitropin alfa/hCG therapy. Follitropin alfa should not be
used when an effective response cannot be obtained.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Semen analysis is
recommended 4 to 6&nbsp;months after the beginning of treatment as part of the
assessment of the response.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Benzalkonium
chloride content</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Ovaleap contains 0.02 mg/mL of benzalkonium chloride</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Benzyl
alcohol content</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ovaleap
contains </span><span lang=EN-GB>10.0 mg per mL benzyl alcohol</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Benzyl
alcohol may cause allergic reactions.</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>High volumes
should be used with caution and only if necessary, especially in subjects with
liver or kidney impairment as well as in pregnant women or while
breast-feeding, because of the risk of accumulation and toxicity (metabolic
acidosis).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Sodium
content</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Ovaleap contains less than 1&nbsp;mmol sodium (23&nbsp;mg)
per dose, that is to say essentially sodium­free.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5     Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Concomitant use of follitropin alfa with other medicinal
products used to stimulate ovulation (e.g. hCG, clomifene citrate) may
potentiate the follicular response, whereas concurrent use of a GnRH agonist or
antagonist to induce pituitary desensitisation may increase the dose of
follitropin alfa needed to elicit an adequate ovarian response. No other
clinically significant medicinal product interaction has been reported during
follitropin alfa therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.6     </span></b><b><span lang=EN-GB>Fertility, p</span></b><b><span
lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Pregnancy</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>There is no indication
for use of Ovaleap during pregnancy. Data on a limited number of exposed
pregnancies (less than 300 pregnancy outcomes) indicate no malformative or
foeto/neonatal toxicity of follitropin alfa.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>No teratogenic effect
has been observed in animal studies (see section 5.3). In case of exposure
during pregnancy, clinical data are not sufficient to exclude a teratogenic
effect of follitropin alfa.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Breast&#8209;feeding</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Ovaleap is not
indicated during breast&#8209;feeding.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Fertility</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Ovaleap is indicated
for use in infertility (see section 4.1).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Ovaleap has no or negligible influence on
the ability to drive and use machines.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Summary of the
safety profile</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The most commonly
reported adverse reactions are headache, ovarian cysts and local injection site
reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the
site of injection).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Mild or moderate OHSS
has been commonly reported and should be considered as an intrinsic risk of the
stimulation procedure. Severe OHSS is uncommon (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Thromboembolism may
occur very rarely (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Tabulated list of
adverse reactions</span></u></i></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-85.05pt'><span
lang=EN-GB>The adverse reactions are ranked under heading of frequency using
the following convention: very</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-85.05pt'><span
lang=EN-GB>common (&#8805;1/10), common (&#8805;1/100 to &lt;1/10), uncommon (&#8805;1/1,000
to &lt;1/100), rare (&#8805;1/10,000 to</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-85.05pt'><span
lang=EN-GB>&lt;1/1,000), very rare (&lt;1/10,000) and not known (cannot be
estimated from the available data). Within</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-85.05pt'><span
lang=EN-GB>each frequency grouping, adverse reactions are presented in order of
decreasing seriousness.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>Treatment in women</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>&nbsp;</span></i></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=614 colspan=3 valign=top style='width:460.6pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table
  1: Adverse reactions in women</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>System
  organ class</span></b></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Frequency</span></b></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Adverse
  reaction</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Immune
  system disorders</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very rare</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Mild to severe hypersensitivity reactions, including anaphylactic
  reactions and shock</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Nervous
  system disorders</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Headache</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='color:black'>Vascular disorders</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very rare</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Thromboembolism (both in association with and separate
  from OHSS)</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='color:black'>Respiratory, thoracic and mediastinal disorders</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very rare</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Exacerbation or aggravation of asthma</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='color:black'>Gastrointestinal disorders</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common:</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Abdominal pain, abdominal distension, abdominal
  discomfort, nausea, vomiting, diarrhoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 rowspan=4 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='color:black'>Reproductive system and breast disorders</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Ovarian cysts</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Mild or moderate OHSS (including associated
  symptomatology)</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Severe OHSS (including associated symptomatology) (see
  section 4.4)</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Rare</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Complication of severe OHSS</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>General
  disorders and administration site conditions</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Injection site reactions (e.g. pain, erythema, haematoma,
  swelling and/or irritation at the site of injection)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-85.05pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-85.05pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-85.05pt'><i><span
lang=EN-GB style='color:black'>Treatment in men</span></i></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-85.05pt'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=614 colspan=3 valign=top style='width:460.6pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table
  2: Adverse reactions in men</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>System
  organ class</span></b></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Frequency</span></b></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Adverse
  reaction</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Immune
  system disorders</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very rare</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Mild to severe hypersensitivity reactions, including
  anaphylactic reactions and shock</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='color:black'>Respiratory, thoracic and mediastinal disorders</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very rare</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Exacerbation or aggravation of asthma</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common:</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Acne</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='color:black'>Reproductive system and breast disorders</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Gynaecomastia, varicocele</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>General
  disorders and administration site conditions</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Injection site reactions (e.g. pain, erythema, haematoma,
  swelling and/or irritation at the site of injection)</span></p>
  </td>
 </tr>
 <tr>
  <td width=205 valign=top style='width:153.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='color:black'>Investigations</span></i></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=205 valign=top style='width:153.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Weight gain</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:lightgrey'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The effects of an
overdose of follitropin alfa are unknown, nevertheless, there is a possibility
that OHSS may occur (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Pharmacotherapeutic
group: Sex hormones and modulators of the genital systems, gonadotropins, ATC
code: G03GA05.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Ovaleap</span><span
lang=EN-GB style='color:black'> is a biosimilar medicinal product. Detailed
information is available on the website of the European Medicines Agency </span><span
lang=EN-GB><a href="http://www.ema.europa.eu"><span style='color:black;
text-decoration:none'>http://www.ema.europa.eu</span></a><span
style='color:black'>.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><i><u><span lang=EN-GB style='color:black'>Pharmacodynamic
effects</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In women, the most important
effect resulting from parenteral administration of FSH is the development of
mature Graafian follicles. In women with anovulation, the object of follitropin
alfa<span style='background:yellow'> </span>therapy is to develop a single
mature Graafian follicle from which the ovum will be liberated after the
administration of hCG.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Clinical efficacy
and safety in women</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In clinical trials,
patients with severe FSH and LH deficiency were defined by an endogenous serum
LH level &lt;&nbsp;1.2&nbsp;IU/L as measured in a central laboratory. However,
it should be taken into account that there are variations between LH
measurements performed in different laboratories.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In clinical studies
comparing r-hFSH (follitropin alfa) and urinary FSH in ART (see table 3 below)
and in ovulation induction, follitropin alfa was more potent than urinary FSH
in terms of a lower total dose and a shorter treatment period needed to trigger
follicular maturation.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In ART, follitropin
alfa at a lower total dose and shorter treatment period than urinary FSH,
resulted in a higher number of oocytes retrieved when compared to urinary FSH.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Table 3: Results of
study GF 8407 (randomised parallel group study comparing efficacy and safety of
follitropin alfa with urinary FSH in ART)</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=536
 style='width:402.3pt;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB style='color:black'>follitropin
  alfa</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>(n = 130)</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB style='color:black'>urinary FSH</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>(n = 116)</span></p>
  </td>
 </tr>
 <tr>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Number of oocytes retrieved</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>11.0 ± 5.9</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>8.8 ± 4.8</span></p>
  </td>
 </tr>
 <tr>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Days of FSH stimulation required</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>11.7 ± 1.9</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>14.5 ± 3.3</span></p>
  </td>
 </tr>
 <tr>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Total dose of FSH required (number of FSH 75&nbsp;IU
  ampoules)</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>27.6 ± 10.2</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>40.7 ± 13.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Need to increase the dose (%)</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>56.2</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>85.3</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Differences between the
2 groups were statistically significant (p&nbsp;&lt;&nbsp;0.05) for all
criteria listed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span lang=EN-GB style='color:black'>Clinical efficacy
and safety in men</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In men deficient in
FSH, follitropin alfa administered concomitantly with hCG for at least
4&nbsp;months induces spermatogenesis.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Following intravenous administration,
follitropin alfa is distributed to the extracellular fluid space with </span><span
lang=EN-GB style='color:black'>an initial half-life of around 2&nbsp;hours and
eliminated from the body with a terminal half-life of about one day. The steady
state volume of distribution and total clearance are 10&nbsp;L and 0.6&nbsp;L/h,
respectively. One&#8209;eighth of the follitropin alfa dose is excreted in the
urine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>Following subcutaneous administration, the absolute
bioavailability is about 70&nbsp;%. Following repeated administration,
follitropin alfa accumulates 3&#8209;fold achieving a steady-state within 3&#8209;4&nbsp;days.
In women whose endogenous gonadotropin secretion is suppressed, follitropin
alfa has nevertheless been shown to effectively stimulate follicular
development and steroidogenesis, despite unmeasurable LH levels. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Non-clinical data reveal no special hazard for humans based
on conventional studies of single and repeated dose toxicity and genotoxicity
additional to that already stated in other sections of this SmPC.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Impaired fertility has
been reported in rats exposed to pharmacological doses of follitropin alfa
(&#8805;&nbsp;40&nbsp;IU/kg/day) for extended periods, through reduced
fecundity.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Given in high doses
(&#8805;&nbsp;5&nbsp;IU/kg/day) follitropin alfa caused a decrease in the
number of viable foetuses without being a teratogen and dystocia similar to
that observed with urinary Menopausal Gonadotropin (hMG). However, since Ovaleap
is not indicated in pregnancy, these data are of limited clinical relevance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Sodium dihydrogen
phosphate dihydrate</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Sodium hydroxide
(2&nbsp;M) (for pH adjustment)</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Mannitol</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Methionine</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Polysorbate 20</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Benzyl alcohol</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Benzalkonium chloride</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In the absence of
compatibility studies, this medicinal product must not be mixed with other
medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:red'>3</span><span lang=EN-GB
style='color:black'> years.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Shelf life</span></u><u><span
lang=EN-GB> and storage conditions after first opening</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The cartridge in&#8209;use
in the pen may be stored for a maximum of 28&nbsp;days. Do not store above
25&nbsp;°C. The patient should write down in the patient diary provided with
the Ovaleap Pen the date of first use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The pen cap must be put
back on the pen after each injection in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Store in a refrigerator
(2&nbsp;°C&nbsp;&#8209;&nbsp;8&nbsp;°C).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep the cartridge in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Before opening and
within its shelf life, the medicinal product may be removed from the
refrigerator, without being refrigerated again, for up to 3&nbsp;months. Do not
store above 25&nbsp;°C. The medicinal product must be discarded if it has not
been used after 3&nbsp;months.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For storage conditions after first opening
of the medicinal product, see section 6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB style='color:black'>Ovaleap
300&nbsp;IU/0.5&nbsp;mL solution for injection</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Cartridge (type I glass) with a rubber piston (bromobutyl
rubber) and a crimp&#8209;cap (aluminium) with a septum (bromobutyl rubber),
containing 0.5&nbsp;mL of solution.<br>
Injection needles (stainless steel; 0.33&nbsp;mm&nbsp;x&nbsp;12&nbsp;mm,
29&nbsp;G&nbsp;x&nbsp;½&quot;)</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black;background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Pack size of
1&nbsp;cartridge and 10&nbsp;injection needles.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black;background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB style='color:black'>Ovaleap
450&nbsp;IU/0.75&nbsp;mL solution for injection</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Cartridge (type I glass) with a rubber piston (bromobutyl
rubber) and a crimp&#8209;cap (aluminium) with a septum (bromobutyl rubber),
containing 0.75&nbsp;mL of solution..<br>
Injection needles (stainless steel; 0.33&nbsp;mm&nbsp;x&nbsp;12&nbsp;mm,
29&nbsp;G&nbsp;x&nbsp;½&quot;)</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Pack size of
1&nbsp;cartridge and 10&nbsp;injection needles.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black;background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB style='color:black'>Ovaleap
900&nbsp;IU/1.5&nbsp;mL solution for injection</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Cartridge (type I glass) with a rubber piston (bromobutyl
rubber) and a crimp&#8209;cap (aluminium) with a septum (bromobutyl rubber),
containing 1.5&nbsp;mL of solution..<br>
Injection needles (stainless steel; 0.33&nbsp;mm&nbsp;x&nbsp;12&nbsp;mm,
29&nbsp;G&nbsp;x&nbsp;½&quot;)</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Pack size of
1&nbsp;cartridge and 20&nbsp;injection needles.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="OLE_LINK1"><b><span lang=EN-GB>6.6     Special precautions for disposal and
other handling</span></b></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No special requirements for disposal.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The solution must not
be used if it contains particles or if the solution is not clear.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Ovaleap is designed for
use in conjunction with the Ovaleap Pen only. The instructions for use of the
pen must be followed carefully.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each cartridge must be
used by a single patient only.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Empty cartridges must
not be refilled. Ovaleap cartridges are not designed to allow any other
medicinal product to be mixed in the cartridges. Discard used needles
immediately after injection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Theramex Ireland Limited</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>3<sup>rd</sup> Floor, </span><span
lang=NL>Kilmore House,</span></p>

<p class=MsoNormal><span lang=NL>Park Lane, Spencer Dock,</span></p>

<p class=MsoNormal><span lang=NL>Dublin 1</span></p>

<p class=MsoNormal><span lang=NL>D01 YE64</span></p>

<p class=MsoNormal><span lang=NL>Ireland</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB style='color:black'>Ovaleap
300&nbsp;IU/0.5&nbsp;mL solution for injection</span></u></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/13/871/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB style='color:black'>Ovaleap
450&nbsp;IU/0.75&nbsp;mL solution for injection</span></u></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/13/871/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u><span lang=EN-GB style='color:black'>Ovaleap 900&nbsp;IU/1.5&nbsp;mL
solution for injection</span></u></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/13/871/003</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Date of first
authorisation: 27 September 2013.</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 16 May 2018.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Detailed
information on this medicinal product </span><span lang=EN-GB>is available on
the website of the European Medicines Agency </span><span lang=EN-GB><a
href="http://www.ema.europa.eu"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a></span><span lang=EN-GB>. </span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.45pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>A.        MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.45pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>B.        CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.45pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>C.        OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:42.45pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>D.        <span style='text-transform:uppercase'>conditions or
restrictions with regard to the safe and effective use of the medicinal product</span></span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A.      MANUFACTURER OF THE BIOLOGICAL ACTIVE
SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><u><span lang=EN-GB>Name and
address of the manufacturer of the biological active substance</span></u></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=DE>Teva Biotech GmbH</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=DE>Dornierstraße 10</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=DE>D-89079 Ulm</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><u><span lang=EN-GB>Name and
address of the manufacturers responsible for batch release</span></u></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=DE>Teva Biotech GmbH</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=DE>Dornierstraße 10</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=DE>D-89079 Ulm</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>Teva
Pharmaceuticals Europe B.V.</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>Swensweg 5</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>NL-2031 GA
Haarlem</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>The
Netherlands</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>Merckle GmbH</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>Graf-Arco-Straße
3</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>89079 Ulm, </span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>The printed
package leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><a name="OLE_LINK2"><span lang=EN-GB>B.</span></a><span
lang=EN-GB>      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF
THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&#9679;       </span><b><span
lang=EN-GB>Periodic Safety Update Reports</span></b></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>The requirements
for submission of periodic safety update reports for this medicinal product are
set out in the list of Union reference dates (EURD list) provided for under
Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on
the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>D.      CONDITIONS OR RESTRICTIONS WITH REGARD
TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-28.4pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'><span
lang=EN-GB>&#9679;       </span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>The MAH shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any
agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>An updated RMP
should be submitted:</span></p>

<p class=MsoNormal style='margin-right:-.05pt;text-indent:14.2pt'><span
lang=EN-GB>&#9679;   </span><span lang=EN-GB>At the request of the European
Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt'><span
lang=EN-GB>&#9679;   </span><span lang=EN-GB>Whenever the risk management
system is modified, especially as the result of new information being received
that may lead to a significant change to the benefit/risk profile or as the
result of an important (pharmacovigilance or risk minimisation) milestone being
reached.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='margin-right:-.05pt;text-align:center'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
300&nbsp;IU/0.5&nbsp;mL solution for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>follitropin&nbsp;alfa</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each cartridge contains
300&nbsp;IU (equivalent to 22&nbsp;micrograms) follitropin alfa in 0.5&nbsp;mL
solution. Each mL of the solution contains 600&nbsp;IU (equivalent to
44&nbsp;micrograms) follitropin alfa.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Excipients: sodium dihydrogen phosphate
dihydrate, sodium hydroxide (2&nbsp;M) (for pH adjustment), mannitol, methionine,
polysorbate 20, benzyl alcohol, benzalkonium chloride, water for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:lightgrey'>Solution
for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1&nbsp;cartridge with 0.5&nbsp;mL
solution and 10&nbsp;injection needles</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>For use only with the
Ovaleap Pen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subcutaneous use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The cartridge in&#8209;use
in the pen may be stored for a maximum of 28&nbsp;days not above 25&nbsp;°C.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Store in a
refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep the cartridge in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>May be stored <span style='color:black'>before
opening not above 25&nbsp;°C for up to 3&nbsp;months. Must be discarded if it
has not been used after 3&nbsp;months.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Theramex Ireland Limited</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>3<sup>rd</sup> Floor, </span><span
lang=NL>Kilmore House,</span></p>

<p class=MsoNormal><span lang=NL>Park Lane, Spencer Dock,</span></p>

<p class=MsoNormal><span lang=NL>Dublin 1</span></p>

<p class=MsoNormal><span lang=NL>D01 YE64</span></p>

<p class=MsoNormal><span lang=NL>Ireland</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/13/871/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
300&nbsp;IU/0.5&nbsp;mL</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
450&nbsp;IU/0.75&nbsp;mL solution for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>follitropin&nbsp;alfa</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each cartridge contains
450&nbsp;IU (equivalent to 33&nbsp;micrograms) follitropin alfa in 0.75&nbsp;mL
solution. Each mL of the solution contains 600&nbsp;IU (equivalent to
44&nbsp;micrograms) follitropin alfa.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Excipients: sodium dihydrogen phosphate
dihydrate, sodium hydroxide (2&nbsp;M) (for pH adjustment), mannitol, methionine,
polysorbate 20, benzyl alcohol, benzalkonium chloride, water for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:lightgrey'>Solution
for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1&nbsp;cartridge with
0.75&nbsp;mL solution and 10&nbsp;injection needles</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>For use only with the
Ovaleap Pen.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subcutaneous use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The cartridge in&#8209;use
in the pen may be stored for a maximum of 28&nbsp;days not above 25&nbsp;°C.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Store in a
refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep the cartridge in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>May be stored <span style='color:black'>before
opening not above 25&nbsp;°C for up to 3&nbsp;months. Must be discarded if it
has not been used after 3&nbsp;months.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Theramex Ireland Limited</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>3<sup>rd</sup> Floor, </span><span
lang=NL>Kilmore House,</span></p>

<p class=MsoNormal><span lang=NL>Park Lane, Spencer Dock,</span></p>

<p class=MsoNormal><span lang=NL>Dublin 1</span></p>

<p class=MsoNormal><span lang=NL>D01 YE64</span></p>

<p class=MsoNormal><span lang=NL>Ireland</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/13/871/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
450&nbsp;IU/0.75&nbsp;mL</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>2D barcode carrying
the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
900&nbsp;IU/1.5&nbsp;mL solution for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>follitropin&nbsp;alfa</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each cartridge contains
900&nbsp;IU (equivalent to 66&nbsp;micrograms) follitropin alfa in 1.5&nbsp;mL
solution. Each mL of the solution contains 600&nbsp;IU (equivalent to
44&nbsp;micrograms) follitropin alfa.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Excipients: sodium dihydrogen phosphate
dihydrate, sodium hydroxide (2&nbsp;M) (for pH adjustment), mannitol, methionine,
polysorbate 20, benzyl alcohol, benzalkonium chloride, water for injections.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:lightgrey'>Solution
for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>1&nbsp;cartridge with
1.5&nbsp;mL solution and 20&nbsp;injection needles</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>For use only with the
Ovaleap Pen.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Subcutaneous use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The cartridge in&#8209;use
in the pen may be stored for a maximum of 28&nbsp;days not above 25&nbsp;°C.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Store in a
refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep the cartridge in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>May be stored <span style='color:black'>before
opening not above 25&nbsp;°C for up to 3&nbsp;months. Must be discarded if it
has not been used after 3&nbsp;months.</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=NL>Theramex Ireland Limited</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>3<sup>rd</sup> Floor, </span><span
lang=NL>Kilmore House,</span></p>

<p class=MsoNormal><span lang=NL>Park Lane, Spencer Dock,</span></p>

<p class=MsoNormal><span lang=NL>Dublin 1</span></p>

<p class=MsoNormal><span lang=NL>D01 YE64</span></p>

<p class=MsoNormal><span lang=NL>Ireland</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/13/871/003</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
900&nbsp;IU/1.5&nbsp;mL</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>2D barcode
carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>CARTRIDGE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
300&nbsp;IU/0.5&nbsp;mL injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>follitropin&nbsp;alfa</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>SC</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>0.5&nbsp;mL</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>CARTRIDGE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
450&nbsp;IU/0.75&nbsp;mL injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>follitropin&nbsp;alfa</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>SC</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>0.75&nbsp;mL</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>CARTRIDGE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB style='color:black'>Ovaleap
900&nbsp;IU/1.5&nbsp;mL injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>follitropin&nbsp;alfa</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>SC</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>1.5&nbsp;mL</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Ovaleap
300&nbsp;IU/0.5&nbsp;mL solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Ovaleap
450&nbsp;IU/0.75&nbsp;mL solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Ovaleap
900&nbsp;IU/1.5&nbsp;mL solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>follitropin
alfa</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you start using this medicine because it contains important information
for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>-        This medicine has been prescribed for you only. Do not pass
it on to others. It may harm them, even if their signs of illness are the same
as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse.</span><span lang=EN-GB> </span><span lang=EN-GB>This
includes any possible side effects not listed in this leaflet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>1.       What Ovaleap is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>2.       What you need to know before you use Ovaleap </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>3.       How to use Ovaleap</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>4.       Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>5.       How to store Ovaleap</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>6.       Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>1.       What
Ovaleap is and what it is used for</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What Ovaleap
is</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This medicine</span><span
lang=EN-GB> contains </span><span lang=EN-GB>the active substance follitropin
alfa, which is almost identical to a natural hormone produced by your body
called follicle&#8209;stimulating hormone (FSH). FSH is a gonadotropin, a
type of hormone that plays an important role in human fertility and
reproduction. In women, FSH is needed for the growth and development of the
sacs (follicles) in the ovaries that contain the egg cells. In men, FSH is
needed for the production of sperm.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What Ovaleap
is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>In adult
women, Ovaleap is used:</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        to help ovulation (release of a mature egg cell from the
follicle) in women that cannot ovulate and that have not responded to treatment
with a medicine called clomifene citrate.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        to help follicles develop in women undergoing assisted
reproductive technology procedures (procedures that may help you to become
pregnant) such as <i>in vitro </i>fertilisation, gamete intra&#8209;fallopian
transfer or zygote intra&#8209;fallopian transfer.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        in combination with a medicine called lutropin alfa (a
version of another gonadotropin, luteinising hormone or LH) to help ovulation
in women that are not ovulating because their body is producing too little FSH
and LH.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>In adult men, Ovaleap is used:</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        in combination with a medicine called human chorionic gonadotropin
(hCG) to help produce sperm in men that are infertile due to low levels of
certain hormones.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>2.       What you need to know before you use Ovaleap</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not use
Ovaleap:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        if you are allergic to follitropin alfa, Follicle Stimulating
Hormone (FSH) or any of the other ingredients of </span><span lang=EN-GB>this
medicine (listed in section 6)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        if you have a tumour in your hypothalamus or pituitary
gland (parts of the brain).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        if you are a <b><i>woman </i></b>with:</span></p>

<p class=MsoNormal style='margin-left:56.7pt'><span lang=EN-GB>- large ovaries
or sacs of fluids within the ovaries (ovarian cysts) of unknown origin.</span></p>

<p class=MsoNormal style='margin-left:56.7pt'><span lang=EN-GB>- unexplained
vaginal bleeding.</span></p>

<p class=MsoNormal style='margin-left:56.7pt'><span lang=EN-GB>- cancer in your
ovaries, womb or breasts.</span></p>

<p class=MsoNormal style='margin-left:56.7pt'><span lang=EN-GB>- any condition
that usually makes normal pregnancy impossible, such as ovarian failure (early menopause),
fibroid tumours of the womb or malformed reproductive organs.</span></p>

<p class=MsoNormal><span lang=EN-GB>        if you are a <b><i>man</i></b>
with:</span></p>

<p class=MsoNormal style='margin-left:56.7pt'><span lang=EN-GB>- testicular
failure that is not treatable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use </span><span lang=EN-GB>this
medicine if any of the above applies to you. If you are not sure, talk to your
doctor or pharmacist before using this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Before the
treatment is started you and your partners fertility should be evaluated by a
doctor experienced in treating fertility disorders.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Porphyria</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor before you start
treatment, if you or any member of your family have porphyria. This is a
condition that may be passed on from parents to children which means that you
have an inability to break down porphyrins (organic compounds).</span></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor straight away if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        your skin becomes fragile and easily blistered, especially
skin that has been frequently in the sun, and/or</span></p>

<p class=MsoNormal><span lang=EN-GB>        you have stomach, arm or leg pain.</span></p>

<p class=MsoNormal><span lang=EN-GB>If you experience the above symptoms your
doctor may recommend that you stop treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Ovarian Hyper&#8209;Stimulation Syndrome
(OHSS)</span></u></p>

<p class=MsoNormal><span lang=EN-GB>If you are a woman, this medicine increases
your risk of developing OHSS. This is when your follicles develop too much and
become large cysts.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor straight away if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        you get pain in the lower part of the abdomen (belly),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        you gain any weight rapidly,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        you feel sick or are vomiting,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        you have difficulty in breathing.</span></p>

<p class=MsoNormal><span lang=EN-GB>If you experience the above symptoms your
doctor might ask you to stop using this medicine (see also section 4</span><span
lang=EN-GB> under </span><span lang=EN-GB>Serious side effects in women&quot;).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are not ovulating and if the
recommended dose and timing are followed, the occurrence of OHSS is less
likely. Ovaleap treatment seldom causes severe OHSS unless the medicine that is
used for final follicular maturation (containing human chorionic gonadotropin,
hCG) is given. If you are developing OHSS your doctor may not give you any hCG
in this treatment cycle. You may be told not to have sex or to use a barrier
contraceptive method for at least 4&nbsp;days.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Multiple pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>When using </span><span lang=EN-GB>this
medicine</span><span lang=EN-GB>, you have a higher risk of being pregnant with
more than one child (i.e. multiple pregnancy, typically twins) than if you
conceived naturally. Multiple pregnancy may lead to medical complications for
you and your babies. You can reduce the risk of multiple pregnancy by using the
right dose of </span><span lang=EN-GB>this medicine</span><span lang=EN-GB> at
the right times. When undergoing assisted reproductive technology the risk of
having a multiple pregnancy is related to your age, the quality and number of fertilised
eggs or embryos placed inside you.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Miscarriage</span></u></p>

<p class=MsoNormal><span lang=EN-GB>You are more likely to have a miscarriage
than the average woman when undergoing assisted reproductive technology or
stimulation of your ovaries to produce eggs.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Ectopic pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>You are more likely to have a pregnancy
outside the womb (an ectopic pregnancy) than the average woman when undergoing
assisted reproductive technology and if you have damaged fallopian tubes.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Birth defects</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>When being conceived by
assisted reproductive technology, a baby may have a slightly higher risk of birth
defects  than after natural conception. This could be related to multiple
pregnancies or to parent characteristics such as maternal age and sperm
characteristics.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Blood clotting problems (thromboembolic
events)</span></u></p>

<p class=MsoNormal><span lang=EN-GB>If you have ever had blood clots in your
leg or lung, or a heart attack or stroke, or if your family have experienced
these, inform your doctor. You might have a higher risk of these problems occurring
or becoming worse with Ovaleap treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Men with too much FSH in their blood</span></u></p>

<p class=MsoNormal><span lang=EN-GB>If you are a man, having too much natural FSH
in your blood can be a sign of damaged testicles. </span><span lang=EN-GB>This
medicine</span><span lang=EN-GB> usually does not work if you have this
problem. If your doctor decides to try Ovaleap treatment, they may monitor it
by asking you to provide semen for analysis 4 to 6&nbsp;months after starting treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal><span lang=EN-GB>T</span><span lang=EN-GB>his medicine</span><span
lang=EN-GB> is not indicated for use in children and adolescents </span><span
lang=EN-GB>less than 18&nbsp;years of age.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Other
medicines and Ovaleap</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Tell your doctor
or pharmacist if you are </span><span lang=EN-GB>using</span><span lang=EN-GB>,
have recently used </span><span lang=EN-GB>or might use </span><span
lang=EN-GB>any other medicines.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        If you use Ovaleap with other medicines which help ovulation
such as human chorionic gonadotropin (hCG) or clomifene citrate, this may
increase the response of your follicles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        If you use Ovaleap at the same time as a
gonadotropin-releasing hormone (GnRH) agonist or antagonist (these medicines
reduce your sex hormone levels and stop you ovulating) you may need a higher
dose of Ovaleap to produce follicles.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Pregnancy and
breast&#8209;feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>You should not use </span><span lang=EN-GB>this
medicine</span><span lang=EN-GB> if you are pregnant or breast&#8209;feeding.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Driving and
using machines</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This medicine
does not affect your ability to drive and use machines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Ovaleap
contains sodium, benzalkonium chloride and benzyl alcohol</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially
sodium-free.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>This
medicine also contains 0.02 mg per mL of benzalkonium chloride and </span><span
lang=EN-GB>10.0 mg per mL of benzyl alcohol. Ask your doctor or pharmacist for
advice if you have a liver or kidney disease, and if you are pregnant or
breast-feeding. This is because large amounts of benzyl alcohol can build-up in
your body and may cause side effects (called metabolic acidosis).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>3.       H</span><span
lang=EN-GB>ow to use Ovaleap</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Always use </span><span
lang=EN-GB>this medicine</span><span lang=EN-GB> exactly as your doctor </span><span
lang=EN-GB>or pharmacist </span><span lang=EN-GB>has told you. Check with your
doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>This medicine
is given as an injection into the tissue just under the skin (subcutaneous
injection). </span><span lang=EN-GB>Your doctor or nurse will show you how to
inject the medicine. If you administer this medicine to yourself, please
carefully read and follow the Instructions for Use of the pen.</span><span
lang=EN-GB style='font-family:"TimesNewRoman",serif'> </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What the </span><span
lang=EN-GB>recommended</span></b><b><span lang=EN-GB> dose is</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Your doctor will decide how much medicine
you will take and how often. The doses described below are stated in
International Units (IU).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Women</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>If you
are not ovulating and have irregular or no periods</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>        This
medicine is usually given every day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        If you have irregular periods, start using this medicine within
the first 7&nbsp;days of your menstrual cycle. If you do not have periods, you
can start using the medicine on any convenient day.</span></p>

<p class=MsoNormal><span lang=EN-GB>        The usual starting dose of this
medicine is 75 to 150&nbsp;IU each day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        Your dose of this medicine may be increased every 7 or
every 14&nbsp;days by 37.5 to 75&nbsp;IU, until you get the desired response.</span></p>

<p class=MsoNormal><span lang=EN-GB>        The maximum daily dose of this
medicine is usually not higher than 225&nbsp;IU.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        When you get the desired response, you will be given hCG or
recombinant hCG (r&#8209;hCG, an hCG made in a laboratory by a special DNA
technique). The single injection will be 250&nbsp;micrograms of r&#8209;hCG or
5,000 to 10,000&nbsp;IU of hCG, 24 to 48&nbsp;hours after your last Ovaleap
injection. The best time to have sex is on the day of the hCG injection and the
day after. Alternatively, intrauterine insemination may be performed by placing
the sperm into the womb cavity.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If your doctor cannot see a desired
response after 4&nbsp;weeks, that treatment cycle with Ovaleap should be
stopped. For the following treatment cycle, your doctor will give you a higher
starting dose of this medicine than before.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If your body responds too strongly, your
treatment will be stopped and you will not be given any hCG [</span><span
lang=EN-GB>see also section 2 under Ovarian Hyper&#8209;Stimulation Syndrome (OHSS)</span><span
lang=EN-GB>]. For the following cycle, your doctor will give you a lower dose
of Ovaleap than before.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>If you need to develop several eggs for
collection prior to any assisted reproductive technology</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        The usual starting dose of this medicine is 150 to
225&nbsp;IU each day, from day&nbsp;2 or 3 of your menstrual cycle.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        The dose may be increased, depending on your response. The
maximum daily dose is 450&nbsp;IU.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        Treatment is continued until your eggs have developed to a
desired point. This usually takes about 10&nbsp;days but can take any time
between 5 and 20&nbsp;days. Your doctor will use blood tests and/or an
ultrasound machine to check when this is.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        When your eggs are ready, you will be given hCG or r&#8209;hCG.
The single injection will be 250&nbsp;micrograms of r&#8209;hCG or 5,000 to 10,000&nbsp;IU
of hCG, 24 to 48&nbsp;hours after the last Ovaleap injection. This gets your
eggs ready for collection.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In other cases, your doctor may first stop
you from ovulating by using a gonadotropin&#8209;releasing hormone (GnRH)
agonist or antagonist. Then Ovaleap is given approximately 2&nbsp;weeks after
the start of agonist treatment. The Ovaleap and GnRH agonist are then both
given until your follicles develop as desired.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>If you are not ovulating, have no
periods and have been diagnosed with very low levels of FSH and LH hormones</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        The usual starting dose of Ovaleap is 75 to 150&nbsp;IU
together with 75&nbsp;IU of lutropin alfa.</span></p>

<p class=MsoNormal><span lang=EN-GB>        You will use these two medicines
each day for up to 5&nbsp;weeks.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        Your dose of Ovaleap may be increased every 7 or every
14&nbsp;days by 37.5 to 75&nbsp;IU, until you get the desired response.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        When you get the desired response, you will be given hCG or
r&#8209;hCG. The single injection will be 250&nbsp;micrograms of r&#8209;hCG or
5,000 to 10,000&nbsp;IU of hCG, 24 to 48&nbsp;hours after your last injections
of Ovaleap and lutropin alfa. The best time to have sex is on the day of the
hCG injection and the day after. Alternatively, intrauterine insemination may
be performed by placing the sperm into the womb cavity.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If your doctor cannot see a response after
5&nbsp;weeks, that treatment cycle should be stopped. For the following cycle,
your doctor will give you a higher starting dose of this medicine than before.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If your body responds too strongly, your
treatment with Ovaleap will be stopped and you will not be given any hCG [</span><span
lang=EN-GB>see also section 2 under Ovarian Hyper&#8209;Stimulation Syndrome
(OHSS)</span><span lang=EN-GB>]. For the following cycle, your doctor will
give you a lower dose of Ovaleap than before.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Men</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>        The
usual dose of this medicine is 150&nbsp;IU together with hCG.</span></p>

<p class=MsoNormal><span lang=EN-GB>        You will use these two medicines
three times a week for at least 4&nbsp;months.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>        If you have not responded to treatment after 4&nbsp;months,
your doctor may suggest that you continue using these two medicines for at
least 18&nbsp;months.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>How are the injections given?</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicine is given as an injection into
the tissue just under the skin (subcutaneous injection) using the Ovaleap&nbsp;Pen.
The Ovaleap&nbsp;Pen is a device (a pen) used for giving injections into the
tissue just under the skin.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Your doctor may
suggest that you learn how to inject yourself with this medicine. Your doctor
or nurse will give you instructions on how to do this and </span><span
lang=EN-GB style='color:black'>you can also find instructions</span><span
lang=EN-GB> in the separate instructions for use of the pen</span><span
lang=EN-GB>. Do not attempt to self&#8209;administer this medicine without this
training by your doctor or nurse. The very first injection of </span><span
lang=EN-GB>this medicine </span><span lang=EN-GB>should only be given in the
presence of a doctor or nurse.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Ovaleap solution
for injection in cartridges has been developed for use in the Ovaleap&nbsp;Pen.
You must follow the separate instructions for use of the Ovaleap&nbsp;Pen
carefully. The instructions for use of the pen will be provided together with
the Ovaleap&nbsp;Pen.</span><span lang=EN-GB> Proper treatment of your condition,
however, requires close and constant co&#8209;operation with your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Discard used
needles immediately after injection.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>If you use
more Ovaleap than you should</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The effects of using
too much Ovaleap are unknown. Nevertheless one could expect Ovarian Hyper&#8209;Stimulation
Syndrome (OHSS) to occur, which is described in section 4 under Serious side
effects in women&quot;. However, the OHSS will only occur if hCG is also
administered [see also section 2 under Ovarian Hyper&#8209;Stimulation
Syndrome (OHSS)].</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB
style='background:yellow'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>If you forget
to use Ovaleap</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use a
double dose to make up for a forgotten dose. Please talk to your doctor as soon
as you realise that you forgot a dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>If you have
any further questions on the use of this medicine, ask your doctor, pharmacist </span><span
lang=EN-GB>or nurse.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><a
name="OLE_LINK6"></a><a name="OLE_LINK7"><b><span lang=EN-GB>4.       Possible
side effects</span></b></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>Like all
medicines, this medicine can cause side effects, although not everybody gets
them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><b><span lang=EN-GB>Important
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><u><span lang=EN-GB>Serious
side effects in men and women</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Allergic reactions such as skin rash, raised itchy areas of
skin and severe allergic reactions with weakness, drop in blood pressure,
difficulty breathing and swelling of the face have been reported very rarely
(may affect up to 1 in 10,000&nbsp;people). If you think you are having this
type of reaction, you must stop your Ovaleap injection and get medical help immediately.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><u><span lang=EN-GB>Serious
side effects in women</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Lower stomach ache together with nausea or vomiting may be
the symptoms of Ovarian Hyper&#8209;Stimulation Syndrome (OHSS). This may
indicate that the ovaries over&#8209;reacted to the treatment and that large
ovarian cysts developed [see also section 2 under Ovarian Hyper&#8209;Stimulation
Syndrome (OHSS)]. This side effect is common (may affect up to 1 in
10&nbsp;people).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        OHSS may become severe with clearly enlarged ovaries,
decreased urine production, weight gain, difficulty in breathing and/or
possible fluid accumulation in your stomach or chest. This side effect is
uncommon (may affect up to 1 in 100&nbsp;people).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Complications of OHSS such as twisting of ovaries or blood
clotting may occur rarely (may affect up to 1 in 1,000&nbsp;people).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Serious blood clotting complications (thromboembolic
events), sometimes independent of OHSS, may be found very rarely (may affect up
to 1 in 10,000&nbsp;people). This could cause chest pain, breathlessness,
stroke or heart attack [see also section 2 under Blood clotting problems
(thromboembolic events)].</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>If you notice
any of the above-listed side effects you should immediately contact your doctor
who may ask you to stop using Ovaleap.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Other side
effects in women</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>Very common</span></u><span
lang=EN-GB> (</span><span lang=EN-GB>may affect more than 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Local reactions at the injection site, such as pain,
redness, bruising, swelling and/or irritation</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Headache</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Sacs of fluid within the ovaries (ovarian cysts)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Common</span></u><span lang=EN-GB> (</span><span lang=EN-GB>may
affect up to 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Stomach ache</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Abdominal bloating</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Abdominal cramps</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Feeling sick</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Vomiting</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Diarrhoea</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Very rare</span></u><span lang=EN-GB> (</span><span lang=EN-GB>may
affect up to 1 in 10,000&nbsp;people)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Your asthma may get worse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>Other side effects in men</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Very common</span></u><span lang=EN-GB> (</span><span lang=EN-GB>may
affect more than 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Local reactions at the injection site, such as pain,
redness, bruising, swelling and/or irritation</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Common</span></u><span lang=EN-GB> (</span><span lang=EN-GB>may
affect up to 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Swelling of the veins above and behind the testicles (a
varicocele)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><a
name="OLE_LINK4"></a><a name="OLE_LINK5"><span lang=EN-GB>        </span></a><span
lang=EN-GB>Breast development</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Acne</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Weight gain</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><u><span
lang=EN-GB>Very rare</span></u><span lang=EN-GB> (</span><span lang=EN-GB>may
affect up to 1 in 10,000&nbsp;people)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>        Your asthma may get worse.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Reporting of
side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, </span><span
lang=EN-GB>talk to your doctor, pharmacist or nurse.</span><span lang=EN-GB>
This includes any possible side effects not listed in this leaflet. You can
also report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>.</span><span
lang=EN-GB>. By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.       How to store Ovaleap</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep </span><span
lang=EN-GB>this medicine </span><span lang=EN-GB>out of the sight and reach of
children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use this
medicine after the expiry date which is stated on the label and outer carton
after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Store in a refrigerator
(2&nbsp;°C&nbsp;&#8209;&nbsp;8&nbsp;°C).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep the cartridge in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Before opening and
within its shelf life, you may remove this medicine from the refrigerator,
without being refrigerated again, for up to 3&nbsp;months. Do not store above
25&nbsp;°C. You must discard this medicine if it has not been used after
3&nbsp;months.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Once opened, the
cartridge in&#8209;use in the pen may be stored for a maximum of 28&nbsp;days.
Do not store above 25&nbsp;°C. Write down the date of first use in the patient
diary, which will be provided with the Ovaleap Pen.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Put the pen cap back
on the <span style='color:black'>Ovaleap Pen</span> after each injection <span
style='color:black'>in order to protect the cartridge from light.</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use this
medicine if you notice i</span><span lang=EN-GB>t is cloudy or there are
particles in it.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not </span><span
lang=EN-GB>throw away any medicines </span><span lang=EN-GB>via wastewater. Ask
your pharmacist how to </span><span lang=EN-GB>throw away </span><span
lang=EN-GB>medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>6.       </span><span
lang=EN-GB>Contents of the pack and other information</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What Ovaleap
contains </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is follitropin alfa.<br>
Ovaleap 300&nbsp;IU/0.5&nbsp;mL: Each cartridge contains 300&nbsp;IU <span
style='color:black'>(equivalent to 22&nbsp;micrograms) </span>follitropin alfa
in 0.5&nbsp;mL solution.<br>
Ovaleap 450&nbsp;IU/0.75&nbsp;mL: Each cartridge contains 450&nbsp;IU <span
style='color:black'>(equivalent to 33&nbsp;micrograms) </span>follitropin alfa
in 0.75&nbsp;mL solution.<br>
Ovaleap 900&nbsp;IU/1.5&nbsp;mL: Each cartridge contains 900&nbsp;IU <span
style='color:black'>(equivalent to 66&nbsp;micrograms) </span>follitropin alfa
in 1.5&nbsp;mL solution.<br>
<span style='color:black'>Each mL of the solution contains 600&nbsp;IU
(equivalent to 44&nbsp;micrograms) follitropin alfa.</span></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients</span><span lang=EN-GB> </span><span
lang=EN-GB>are sodium dihydrogen phosphate dihydrate, sodium hydroxide
(2&nbsp;M) (for pH adjustment), mannitol, methionine, polysorbate&nbsp;20,
benzyl alcohol, benzalkonium chloride and water for injections.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>All strengths
listed above contain the other ingredients.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What Ovaleap
looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Ovaleap</span><span lang=EN-GB> is a
solution for injection (injection). Ovaleap is a clear and colourless solution.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Ovaleap 300&nbsp;IU/0.5&nbsp;mL is
available in packs containing 1&nbsp;cartridge and 10&nbsp;injection needles.<br>
Ovaleap 450&nbsp;IU/0.75&nbsp;mL is available in packs containing
1&nbsp;cartridge and 10&nbsp;injection needles.<br>
Ovaleap 900&nbsp;IU/1.5&nbsp;mL is available in packs containing
1&nbsp;cartridge and 20&nbsp;injection needles.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal><span lang=NL>Theramex Ireland Limited</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>3<sup>rd</sup> Floor, </span><span
lang=NL>Kilmore House,</span></p>

<p class=MsoNormal><span lang=NL>Park Lane, Spencer Dock,</span></p>

<p class=MsoNormal><span lang=NL>Dublin 1</span></p>

<p class=MsoNormal><span lang=NL>D01 YE64</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=NL>Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal><a name="OLE_LINK8"></a><a name="OLE_LINK9"><span
lang=EN-GB>Teva Biotech GmbH</span></a></p>

<p class=MsoNormal><span lang=EN-GB>Dornierstraße 10</span></p>

<p class=MsoNormal><span lang=EN-GB>89079 Ulm</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:silver'><span lang=EN-GB style='color:
black'>Teva Pharmaceuticals Europe B.V.</span></p>

<p class=MsoNormal style='background:silver'><span lang=EN-GB style='color:
black'>Swensweg 5</span></p>

<p class=MsoNormal style='background:silver'><span lang=EN-GB style='color:
black'>2031 GA Haarlem</span></p>

<p class=MsoNormal style='background:silver'><span lang=EN-GB style='color:
black'>The Netherlands</span></p>

<p class=MsoNormal style='margin-right:-28.4pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:silver'><span lang=EN-GB style='color:
black'>Merckle GmbH</span></p>

<p class=MsoNormal style='background:silver'><span lang=EN-GB style='color:
black'>Graf-Arco-Straße 3</span></p>

<p class=MsoNormal style='background:silver'><span lang=EN-GB style='color:
black'>89079 Ulm, </span></p>

<p class=MsoNormal style='background:silver'><span lang=EN-GB style='color:
black'>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>This leaflet
was last </span><span lang=EN-GB>revised in </span></b><span lang=EN-GB>{<b>month
YYYY</b>}<b>.</b></span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: </span><span lang=EN-GB><a href="http://www.ema.europa.eu"><span
style='color:windowtext;text-decoration:none'>http://www.ema.europa.eu</span></a></span><span
lang=EN-GB>.</span></p>

</div>

</body>

</html>
